New technique extends cancer-fighting cells' potency in melanoma patients

Scientists have developed a technique -- a form of "adoptive immunotherapy" -- that can enable anti-tumor T cells to survive in melanoma patients' bloodstreams for well over a year, in some cases. The results represent the longest that injected anti-tumor T cells have ever endured in cancer patients without the use of supplemental treatments.

Read the whole article on Science Daily

More from Science Daily